Federated Hermes
ANTX icon

Federated Hermes’s AN2 Therapeutics ANTX Stock Holding History

Federated Hermes’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5K Sell
8,322
-3,157
-28% -$6.51K ﹤0.01% 1743
2025
Q4 		$13.1K Sell
11,479
-403
-3% -$471 ﹤0.01% 1813
2025
Q3 		$15.1K Sell
11,882
-355
-3% -$406 ﹤0.01% 1837
2025
Q2 		$13K Hold
12,237
– – ﹤0.01% 1777
2025
Q1 		$16.6K Buy
12,237
+4,745
+63% +$5.97K ﹤0.01% 1754
2024
Q4 		$10.3K Buy
7,492
+4,486
+149% +$5.44K ﹤0.01% 1837
2024
Q3 		$3.22K Buy
3,006
+2,089
+228% +$3.63K ﹤0.01% 1901
2024
Q2 		$1.97K Buy
917
+706
+335% +$1.68K ﹤0.01% 1901
2024
Q1 		$686 Sell
211
-47
-18% -$511 ﹤0.01% 1976
2023
Q4 		$5.29K Buy
258
+160
+163% +$2.68K ﹤0.01% 1847
2023
Q3 		$1.58K Buy
+98
New +$1.11K ﹤0.01% 1986

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Federated Hermes's ANTX Position: Q1 2026 in Review

Federated Hermes reduced its AN2 Therapeutics (ANTX) stake by 28% in Q1 2026, selling an estimated $6.51K and leaving 8,322 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Federated Hermes first reported a position in ANTX in Q3 2023 and has held it in 11 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Federated Hermes held 8,322 shares of AN2 Therapeutics worth $28.5K as of Q1 2026.
  • Federated Hermes sold 3,157 AN2 Therapeutics shares in Q1 2026, an estimated $6.51K.
  • AN2 Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1743 holding.
  • Federated Hermes first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.